Acne Treatment Pads Recalled for Subpotent Salicylic Acid Levels
Huijing (Shanghai) Bio-tech Co., Ltd. is recalling Acne Treatment Pads because the active ingredient level does not match the label.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which is defined as unlikely to cause adverse health consequences. The hazard is a labeling/potency discrepancy without reported injuries.
Plain-English summary
Huijing (Shanghai) Bio-tech Co., Ltd. is recalling Acne Treatment Pads (2% salicylic acid) packaged in 50-count jars. The recall is due to the product being subpotent, meaning the active ingredient level does not match the exact levels indicated on the packaging label.
The affected product is identified by Lot # 2458067 and has an expiration date of 11/2019. The product was distributed to one distributor in Virginia. The total quantity involved is 75,000 pads.
Consumers should stop using the product and contact the distributor or manufacturer for further instructions.
The recalled product
- Product
- Acne Treatment Pads (2% salicylic acid), packaged in a 50-count jar, OTC, Distributed by: Greenbrier International, Inc. 500 Volvo Parkway, Chesapeake, VA 23320, NDC 71537-001-02
- Manufacturer
- Huijing (Shanghai) Bio-tech Co., Ltd.
- Category
- Drug — Over-the-Counter Topical
- Affected units
- 75,000
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 2458067
- Exp 11/2019
Distribution
Distributed in 1 state:
Related recalls
Same hazard · subpotent drug
See all →- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02